Patent · US Active

NK-3 receptor antagonists for therapeutic treatment of leptin-related disease

US11478472B2 · kind B2 · utility

0Cited by
6References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 20, 2020
Grant dateOct 25, 2022
Priority date—
Expiry dateJan 13, 2041

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P3/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed is use of NK3R antagonists for the therapeutic treatment leptin-related disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.